NCT07610538Recruiting
Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
The primary goals of this study are to compare the differences in tissue-resident Treg gene signature for activation, proliferation, and suppressive function using single-cell/-nucleus RNA sequencing in patients treated with ld-IL-2 compared to control grouped by individual tissue beds from in and around the heart. Additionally, tissue-resident Tregs will be compared to peripheral blood Tregs from the same patient to assess the differential effect of ld-IL-2 on the two compartments.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 20 May 2026
- Start date
- 31 Mar 2026
- Primary completion date
- 1 Nov 2028
- Lead sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Diseases
- Coronary artery disease
- NCT number
- NCT07610538
What you commit to
- Study type: Interventional
- Planned participants: 24
- From 31 Mar 2026 to the primary completion date, 1 Nov 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any regular immunosuppressive treatment \[Inhaled or topical steroids are permissible\]
- Vaccine within 4 weeks prior to screening
Other illness
- Critical left main stem coronary disease
- Severe valvular disease (for example 'severe' aortic stenosis as classified on echocardiogram report)
- Haemodynamic instability caused by arrhythmia requiring cardioversion in the current admission
- Autoimmune disease
- Allergy or intolerance to aldesleukin
- Signs and symptoms of active infection
- History of human immunodeficiency virus (HIV), hepatitis B or C
- Current malignancy requiring active treatment
- Clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study
Lab values
- Known active hepatic disease or alanine aminotransferase (ALT) \> 3xULN
- Severe chronic kidney disease (defined as eGFR \< 30 ml/min/1.73m2)
Age
- Women of child-bearing potential and pregnancy (women must be either postmenopausal (defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile (e.g. age appropriate (\>55 years old), history of vasomotor symptoms) or having documented hysterectomy and/or bilateral oophorectomy)
Other
- Non-sustained ventricular tachycardia of \>10 beats in the last 48 hours
- Women who are breast-feeding
Who the study is looking for
- Aged over 18 years old
- Undergoing CABG surgery
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Papworth Hospital NHS Foundation Trust Coordinator of this site? Confirm its status | Cambridge | United Kingdom | Recruiting |
| Addenbrooke's Hospital Coordinator of this site? Confirm its status | Cambridge | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.